Cargando…

Circular RNA circSMARCA5 is a prognostic biomarker in patients with malignant tumor: a meta-analysis

BACKGROUND: Malignant tumor is one of the most serious diseases endangering human health. Circular RNAs play an important role in the tumorigenesis and progression of various malignant tumors. Although various studies have investigated the biological function of circular RNA circSMARCA5 in malignant...

Descripción completa

Detalles Bibliográficos
Autores principales: Chao, Fan, Wang, Shiyu, Zhang, Cong, Han, Dunsheng, Ma, Zhe, Chen, Gang
Formato: Online Artículo Texto
Lenguaje:English
Publicado: BioMed Central 2021
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8145840/
https://www.ncbi.nlm.nih.gov/pubmed/34034688
http://dx.doi.org/10.1186/s12885-021-08316-3
_version_ 1783697262194458624
author Chao, Fan
Wang, Shiyu
Zhang, Cong
Han, Dunsheng
Ma, Zhe
Chen, Gang
author_facet Chao, Fan
Wang, Shiyu
Zhang, Cong
Han, Dunsheng
Ma, Zhe
Chen, Gang
author_sort Chao, Fan
collection PubMed
description BACKGROUND: Malignant tumor is one of the most serious diseases endangering human health. Circular RNAs play an important role in the tumorigenesis and progression of various malignant tumors. Although various studies have investigated the biological function of circular RNA circSMARCA5 in malignant tumors, the prognostic value of circSMARCA5 in malignant tumor patients has not been systematically analyzed. METHODS: Relevant studies were obtained from the PubMed and Web of Science database. The quality of the enrolled studies was evaluated using the Newcastle-Ottawa Scale quality assessment system. Survival features and clinicopathological features were assessed using pooled hazard ratios and odds ratios with 95% confidence intervals, respectively. RESULTS: Overall, 7 relevant publications were enrolled in the meta-analysis. CircSMARCA5 expression was significantly correlated with better OS (HR = 0.51, 95%CI 0.41–0.65) or DFS/RFS/PFS (HR = 0.56, 95%CI 0.43–0.73) in malignant tumors. In the pooled analyses of clinicopathological characteristics, malignant tumors with higher circSMARCA5 were better differentiated (OR = 0.41, 95%CI 0.19–0.88). CircSMARCA5 expression was correlated with less advanced TNM stage (OR = 0.33, 95%CI 0.19–0.55). Moreover, malignant tumors with higher circSMARCA5 expression have less advanced lymph node metastasis (OR = 0.26, 95%CI 0.08–0.79). CONCLUSION: These results indicated that circSMARCA5 was a promising biomarker in malignant tumors, which may potentially facilitate clinical decisions in the future. SUPPLEMENTARY INFORMATION: The online version contains supplementary material available at 10.1186/s12885-021-08316-3.
format Online
Article
Text
id pubmed-8145840
institution National Center for Biotechnology Information
language English
publishDate 2021
publisher BioMed Central
record_format MEDLINE/PubMed
spelling pubmed-81458402021-05-25 Circular RNA circSMARCA5 is a prognostic biomarker in patients with malignant tumor: a meta-analysis Chao, Fan Wang, Shiyu Zhang, Cong Han, Dunsheng Ma, Zhe Chen, Gang BMC Cancer Research Article BACKGROUND: Malignant tumor is one of the most serious diseases endangering human health. Circular RNAs play an important role in the tumorigenesis and progression of various malignant tumors. Although various studies have investigated the biological function of circular RNA circSMARCA5 in malignant tumors, the prognostic value of circSMARCA5 in malignant tumor patients has not been systematically analyzed. METHODS: Relevant studies were obtained from the PubMed and Web of Science database. The quality of the enrolled studies was evaluated using the Newcastle-Ottawa Scale quality assessment system. Survival features and clinicopathological features were assessed using pooled hazard ratios and odds ratios with 95% confidence intervals, respectively. RESULTS: Overall, 7 relevant publications were enrolled in the meta-analysis. CircSMARCA5 expression was significantly correlated with better OS (HR = 0.51, 95%CI 0.41–0.65) or DFS/RFS/PFS (HR = 0.56, 95%CI 0.43–0.73) in malignant tumors. In the pooled analyses of clinicopathological characteristics, malignant tumors with higher circSMARCA5 were better differentiated (OR = 0.41, 95%CI 0.19–0.88). CircSMARCA5 expression was correlated with less advanced TNM stage (OR = 0.33, 95%CI 0.19–0.55). Moreover, malignant tumors with higher circSMARCA5 expression have less advanced lymph node metastasis (OR = 0.26, 95%CI 0.08–0.79). CONCLUSION: These results indicated that circSMARCA5 was a promising biomarker in malignant tumors, which may potentially facilitate clinical decisions in the future. SUPPLEMENTARY INFORMATION: The online version contains supplementary material available at 10.1186/s12885-021-08316-3. BioMed Central 2021-05-25 /pmc/articles/PMC8145840/ /pubmed/34034688 http://dx.doi.org/10.1186/s12885-021-08316-3 Text en © The Author(s) 2021 https://creativecommons.org/licenses/by/4.0/Open AccessThis article is licensed under a Creative Commons Attribution 4.0 International License, which permits use, sharing, adaptation, distribution and reproduction in any medium or format, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons licence, and indicate if changes were made. The images or other third party material in this article are included in the article's Creative Commons licence, unless indicated otherwise in a credit line to the material. If material is not included in the article's Creative Commons licence and your intended use is not permitted by statutory regulation or exceeds the permitted use, you will need to obtain permission directly from the copyright holder. To view a copy of this licence, visit http://creativecommons.org/licenses/by/4.0/ (https://creativecommons.org/licenses/by/4.0/) . The Creative Commons Public Domain Dedication waiver (http://creativecommons.org/publicdomain/zero/1.0/ (https://creativecommons.org/publicdomain/zero/1.0/) ) applies to the data made available in this article, unless otherwise stated in a credit line to the data.
spellingShingle Research Article
Chao, Fan
Wang, Shiyu
Zhang, Cong
Han, Dunsheng
Ma, Zhe
Chen, Gang
Circular RNA circSMARCA5 is a prognostic biomarker in patients with malignant tumor: a meta-analysis
title Circular RNA circSMARCA5 is a prognostic biomarker in patients with malignant tumor: a meta-analysis
title_full Circular RNA circSMARCA5 is a prognostic biomarker in patients with malignant tumor: a meta-analysis
title_fullStr Circular RNA circSMARCA5 is a prognostic biomarker in patients with malignant tumor: a meta-analysis
title_full_unstemmed Circular RNA circSMARCA5 is a prognostic biomarker in patients with malignant tumor: a meta-analysis
title_short Circular RNA circSMARCA5 is a prognostic biomarker in patients with malignant tumor: a meta-analysis
title_sort circular rna circsmarca5 is a prognostic biomarker in patients with malignant tumor: a meta-analysis
topic Research Article
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8145840/
https://www.ncbi.nlm.nih.gov/pubmed/34034688
http://dx.doi.org/10.1186/s12885-021-08316-3
work_keys_str_mv AT chaofan circularrnacircsmarca5isaprognosticbiomarkerinpatientswithmalignanttumorametaanalysis
AT wangshiyu circularrnacircsmarca5isaprognosticbiomarkerinpatientswithmalignanttumorametaanalysis
AT zhangcong circularrnacircsmarca5isaprognosticbiomarkerinpatientswithmalignanttumorametaanalysis
AT handunsheng circularrnacircsmarca5isaprognosticbiomarkerinpatientswithmalignanttumorametaanalysis
AT mazhe circularrnacircsmarca5isaprognosticbiomarkerinpatientswithmalignanttumorametaanalysis
AT chengang circularrnacircsmarca5isaprognosticbiomarkerinpatientswithmalignanttumorametaanalysis